Amgen Inc. on April 27 said the U.S. Internal Revenue Service (IRS) is seeking additional back taxes of $5.1 billion, plus interest and penalties, related to the drugmaker’s 2013 to 2015 accounting for profits between the United States and Puerto Rico, the location of most of the company’s manufacturing operations.
Amgen and AstraZeneca unveiled their first, direct-to-consumer U.S. advertising campaign in severe asthma called “Be You.” Launching ahead of Asthma & Allergy Awareness Month in May, the “Be You” campaign leverages visually distinct animated characters who do not let their disease define them. The campaign aims to raise awareness about a new severe asthma medicine called TEZSPIRE (tezepelumab-ekko).
Amgen posted a 3 percent rise in total 2021 fourth-quarter revenue to $6.8 billion and a 2 percent increase in total revenue for the year to $26 billion, driven mainly through wins from “other” gains.
Amgen Chief Executive Officer Robert Bradway is excited about 2022. During his presentation at the J.P. Morgan Healthcare Conference, Bradway said things are lining up for long-term growth for the California-based company.
Amgen and Generate Biomedicines inked a research partnership to discover and develop protein therapeutics for five clinical targets.
The U.S. Food and Drug Administration approved AstraZeneca and Amgen’s drug Tezspire to treat severe asthma for those aged 12 years and older, the companies said on December 17.
J.P. Morgan Chase put an end to the uncertainty surrounding its annual health care conference, announcing that the 40th edition will move to a virtual format.
Amgen’s oral drug candidate for genital psoriasis delivered positive topline results from a Phase III trial, with both primary and secondary endpoints met by Otezla (apremilast).
Janssen Pharmaceutical and Amgen received another regulatory win for Darzalex Faspro (daratumumab and hyaluronidase-fihj) as the U.S. Food and Drug Administration approved the drug in combination with Amgen’s Kyprolis (carfilzomib) and dexamethasone for the treatment of adults with relapsed or refractory multiple myeloma who have received one to three prior lines of therapy.
Amgen announced that the company’s Aimovig (erenumab-aooe) more than held the approved therapy’s ground against one of the most commonly prescribed migraine medications.
